Mumbai-based nutrition startup Ace Blend has raised $9.91 million in a Series A2 funding round led by 3one4 Capital, with participation from existing investor Fireside Ventures.
/indianstartupnews/media/media_files/2026/06/17/desktop-728-x-90-1-2026-06-17-17-20-35.png)
Prior to this, Fireside Ventures had led Ace Blend’s $3.3 million pre-Series A round in August 2025.
The startup will use the fresh capital for research-led product development and bring new nutrition formats to market. It claims it grew 300% in FY26, and that more than 46% of its customers come back to buy again.
Founder Shivam Hingorani said the funding will be used to conduct clinical trials through contract research organisations (CROs), with plans to publish the findings in peer-reviewed international journals.
The startup aims to strengthen its supply chain capabilities and develop an automated system to test every batch for nutritional accuracy, pesticide residues and heavy metals without human intervention.
It plans to conduct shelf-stability studies at launch and again six months later, while sourcing raw materials from multiple countries.
Products in development include a formulation made with a gut-health specialist to address leaky gut, a mix of natural nutrients meant to lower inflammation, an eye-health product and a fibre-based format for gut health, Hingorani said.
Ace Blend is targeting annual recurring revenue of Rs 250-300 crore over the next 12-18 months, with profitability also in sight, he added.
What Ace Blend does
Hingorani started selling Ace Blend products in 2018. Saif Mehkri joined as co-founder in 2022, bringing nearly three decades of experience in the nutrition industry.
The startup sells around 14 SKUs, including plant-based protein powders, superfood mixes and functional supplements for heart health, brain health, sleep, recovery, gut health, strength and immunity.
It also offers functional drinks such as mushroom coffees and lattes, along with supplements including omega-3, magnesium, multivitamins and creatine.
About half of its revenue comes from its own website. The rest comes from marketplaces and quick commerce platforms, including Amazon, Flipkart, Zepto and Blinkit.
Ace Blend said it starts with clinical evidence and then decides the nutrient form, dosage and delivery method, rather than picking popular ingredients and looking for studies to support them. It runs an integrated supply chain that covers ingredient sourcing, formulation and manufacturing, instead of relying on contract manufacturers.
Global ingredient suppliers DSM and TCI have given the company exclusive rights in India to some of their technologies. Its products are developed by an in-house clinical team and recommended by a network of more than 400 doctors, the startup said. Clinical validation and automated testing are carried out independently by accredited laboratories in Europe.
It also holds issued patents on new nutrition formats designed for everyday use. The first of these is expected to reach the market in the fourth quarter of FY27, which runs from January to March 2027.
“The world around us is accelerating far faster than our biology can keep up. That gap is where so many modern deficiencies and diseases live. Our work is to close it, with powerful nutrients that go beyond what our plates can offer, backed by clinical evidence,” Hingorani said.
Pranav Pai, Managing Partner at 3one4 Capital, said, “In a crowded category where low-moat brands behave like traders and compete only on marketing, Ace is scaling science-led formulations and a trust-first approach with rigorous focus on ingredient quality, sourcing discipline, and manufacturing specialisation.”
3one4 Capital’s portfolio already includes consumer brands such as Licious and Kapiva.
Ankita Balotia, Principal at Fireside Ventures, said the team identified unmet needs in Indian nutrition early. “But the strongest validation comes from consumers themselves; high repeat rates and positive word of mouth reflect the trust the brand has earned,” she said.
Ace Blend competes in a fast-growing category. According to Grand View Research, India’s dietary supplements market was worth $5.8 billion in 2025 and is projected to reach $12.4 billion by 2033, growing at about 9.5% a year between 2026 and 2033.
The research firm estimates that offline channels accounted for 80.6% of the market’s revenue in 2025, while online distribution is expected to grow at 10% a year.
